Shanxi Province Cancer Hospital clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-20
What changed in the last 30 days
3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.
- Notable: Precision · Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib Primary completion pushed from Oct 15, 2028 to May 15, 2029
- Minor: Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Notable: Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer Enrollment increased: 30 → 50 participants
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 1/2 | 1 | |
| Phase 2 | 2 |
Disease areas by active trials
Bladder Cancer (1) · Lung Cancer (1) · Mantle Cell Lymphoma (1) · Non-Hodgkin Lymphoma (1) · Non-Small Cell Lung Cancer (NSCLC) (1)
Get alerts when Shanxi Province Cancer Hospital's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.